Multiple widespread fixed drug eruption caused by in a transdermal therapeutic system
Contact Dermatitis · 2024
DOI: 10.1111/cod.14542 ↗At a glance
Fallbericht in Contact Dermatitis, 2024. Written by Laura Taboada Paz and 6 co-authors. Institution: Dermatology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain. Major MEDLINE topics: Drug Eruptions. 10 references.
Abstract (original language)
Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterised by skin lesions that recur in the same sites upon re-exposure to the same or a related drug. New lesions may emerge in other locations as well after further administration of the culprit drug. We report a case of multiple fixed drug caused by oxybutynin, in a transdermal therapeutic systems (TTS) in a patient treated for urinary incontinence. A 83-year-old man presented to our clinic with multiple, oval, erythematous-brownish plaques on his back and forearms (Figure 1). The patient had experienced episodes of similar skin lesions in the same locations for the past 6 months. The most extensive plaques were observed in the region where the oxybutynin patch (Kentera®) had been applied for the past 6 years to manage urge urinary incontinence. The patient has never taken oxybutynin orally. Upon systemic examination, no abnormalities were noted. The patient reported no changes in his oral medications. Histological examination of one of the skin lesions revealed Interface dermatitis characterised by abundant necrotic keratinocytes, vacuolisation of the basal layer of the epidermis (Civatte bodies), and pigmentary incontinence, with a marked presence of melanophages in the papillary dermis (Figure 2). We performed patch testing with the TRUE Test, supplemented with an allergens by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) and our adhesive series. Patch tests with 0.1% and 1% oxybutynin in petrolatum, and Kentera® patch were applied under occlusion for 48 h on residuals pigmented lesions and normal skin of the back. Readings were done 2 and 4 days later according to International Contact Dermatitis Research Group (ICDRG) guidelines. Patch test showed positive results (+) at 2 and 4 days by 0.1% and 1% oxybutynin and Kentera® patch at the lesional skin only. The other tests remaining negative. The patient has since avoided oxybutynin and no recurrence of the skin symptoms has been observed. We present a case of multiple widespread fixed drug eruptions caused by oxybutynin plaster. The diagnosis was suspected based on clinical appearance and histology, and was confirmed by a positive lesional patch test. Drug-related application-site reactions associated with oxybutynin transdermal therapeutic systems have been described. The most common skin reactions included pruritus, erythema, dermatitis and irritation.1, 2 In agreement with previous studies, patch testing on lesional skin was useful to confirm oxibutinyn as the culprit drug in this generalised FDE case. It should be highlighted that patch testing must be performed on residual lesional areas, where intraepidermal CD8+ effector/memory T cells are retained for many years. This probably facilitates reactivation after cutaneous exposure due to patch testing.3 The most common causative drugs of FDE are NSAIDs, acetaminophen, antibiotics and antiepileptics. However, there's a multitude of substances that have been implicated in FDE, including intravenous contrast agents, the influenza vaccine, and even certain foods.4 We have only found one case report of fixed drug eruption secondary to oxybutynin.5 FDE is typically associated with the consumption of oral medication. To date, there have been few reported cases associated with topical agents: plaster with Chinese herbs,6 intravaginal metronidazole ovules,7 analgesic plaster containing piroxicam,8 olopatadine ophthalmic solution9 and phenobarbital-containing suppositories.10 This demonstrates that FDE can appear after exposure to topical medications but high individual sensitivity is probably necessary. Our patient had been exposed to oxybutynin patches for years; we think that such an extended period of exposure was necessary to produce CD8 memory T cells that reacted due to the low blood drug concentration. To our knowledge, this is the first case of multiple FDE due to topical oxybutinin. Laura Taboada Paz: Conceptualization; investigation; writing – original draft; methodology; validation; writing – review and editing; visualization; software; project administration; data curation; supervision; resources. Pilar Iriarte Sotés: Conceptualization; investigation; writing – original draft; methodology; validation; writing – review and editing; supervision; resources. Elena Vicente Basanta: Validation; visualization; resources; supervision; writing – original draft. Silvia Ojea Varona: Supervision; resources; validation; visualization; writing – original draft. Adrián Santiago López Caamaño: Writing – original draft; validation; visualization; supervision; resources. Laura López Solache: Writing – original draft; validation; visualization; supervision; resources; writing – review and editing; investigation. Benigno Monteagudo Sanchez: Conceptualization; investigation; writing – original draft; supervision; resources; writing – review and editing; validation; visualization.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Dermatology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.
- Allergology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.
- Pathology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.
ORCID profiles: Laura Taboada Paz
Cite
APA
Taboada Paz, L., Iriarte Sotés, P., Vicente Basanta, E., Ojea Varona, S., López Caamaño, A. S., López Solache, L., & Monteagudo Sanchez, B. (2024). Multiple widespread fixed drug eruption caused by in a transdermal therapeutic system. Contact Dermatitis. https://doi.org/10.1111/cod.14542
Vancouver
Taboada Paz L, Iriarte Sotés P, Vicente Basanta E, Ojea Varona S, López Caamaño AS, López Solache L, et al. Multiple widespread fixed drug eruption caused by in a transdermal therapeutic system. Contact Dermatitis. 2024. doi:10.1111/cod.14542
BibTeX
@article{TaboadaPaz2024,
author = {Taboada Paz, Laura and Iriarte Sotés, Pilar and Vicente Basanta, Elena and Ojea Varona, Silvia and López Caamaño, Adrián Santiago and López Solache, Laura and Monteagudo Sanchez, Benigno},
title = {Multiple widespread fixed drug eruption caused by in a transdermal therapeutic system},
journal = {Contact Dermatitis},
year = {2024},
doi = {10.1111/cod.14542}
}
EUVIMED